The MOU was signed on May 16 during the MIXiii Biomed 2018 in Tel Aviv by Suzanne Ali-Hassan, head of corporate affairs for the NHSA, and British Ambassador to Israel David Quarrey.
The joint working arrangement will support innovative Israeli healthcare companies establishing research and a presence in the north of England, Ali-Hassan said.
“There are well over 1,400 life-science and healthcare companies in Israel whose innovations have the potential to bring great benefits to the North’s hospitals and patient population,” she said.
The Northern Health Science Alliance (NHSA) brings together eight research-intensive universities, eight NHS teaching hospitals and four academic health science networks for the benefit of the region’s population of 15 million.
“The agreement will further enable British researchers and patients to have access to the latest technology from Israel. And we hope even more Israeli medical companies will now look to the UK as a destination for their growth,” said Quarrey.
NHSA will provide support to Israeli companies identified by UK Israel Tech Hub to access the clinical research environment in the North of England. The UK Israel Tech Hub will assist Israeli companies in securing and developing partnerships and collaborations via the NHSA.
UK Israel Tech Hub was launched at the British Embassy Israel in 2011 to create partnerships in which British companies gain a global competitive edge via Israeli innovation, and Israeli innovation goes global via the UK.
MIXiii-Biomed attracted more than 6,000 industry executives, scientists, doctors, engineers and investors, including approximately 1,000 international participants from 45 countries.